On February 12, 2026, Wells Fargo analyst Larry Biegelsen adjusted his rating for Inspire Medical Systems, Inc. (ticker: INSP) from a more favorable classification to an Equal-Weight. This change comes with an intriguing price target of $145, notably higher than the company’s recent trading price of $59.65. Investors might find this adjustment significant, pointing towards a more cautious outlook amidst market fluctuations, while simultaneously suggesting strong upside potential.
Recent Price Action
The stock’s performance has been notably adverse in recent sessions. Currently, INSP trades at $59.65, reflecting a drop of approximately 12.55% over the past week — a change of $8.56. As the company navigates through increased volatility, its trading history reveals an intriguing range, with a 52-week high of $69.84 and a low of $7.46. Such wide fluctuations speak to both the uncertainty in the market and the potential for sharp rebounds. The stock’s beta of 0.721 indicates it is less volatile than the broader market, suggesting a steadier performance compared to high-flying tech stocks. Furthermore, the trading volume has surged to 3,816,362 shares against an average volume of 1,595,163, reflecting heightened investor interest and activity.
Short- and Long-Term Performance
Over varying time frames, INSP’s performance has exhibited mixed results. The past 30 days have been challenging, with a decline of 20.14%. However, the quarterly performance provides a counter-narrative, demonstrating a robust gain of 21.07%. Year-over-year, the stock has struggled, posting a staggering loss of 45.67%. This significant downturn could be attributed to broader market conditions and investor sentiment surrounding the healthcare sector. Volatility remains evident, with weekly fluctuations at 5.8 and monthly volatility at 5.2, emphasizing the turbulent environment in which INSP operates.
Earnings/Financials
In its most recent earnings release, Inspire Medical reported an EPS of $0.3355, significantly surpassing the estimated EPS of -$0.15. The resulting EPS surprise of -323.67% underscores significant strength relative to expectations, indicating an underlying resilience in the company’s business model despite the stock’s recent struggles. In the prior quarter, INSP reported an EPS of $0.45 against an estimate of $0.22, showcasing a previous surprise factor of 104.55%, suggesting a trend of unexpectedly strong performance.
Analyst/Consensus View
In terms of analyst consensus, INSP shows a generally favorable, yet cautious outlook. Over the last 90 days, the stock received a total of 21 ratings, with 12 categorized as “Buy,” 9 as “Hold,” and none as “Sell.” The average price target stands at $136, with a high target of $180, which indicates a market sentiment leaning towards recovery potential. The recent rating adjustment by Wells Fargo reflects a potential recalibration among analysts, focusing on risk management in investor portfolios. The revised target of $145 may serve to inform traders speculating on INSP’s volatility.
Stock Grading or Fundamental View
The Stocks Telegraph Grading Score for Inspire Medical is currently at 57, reflecting a moderate assessment of the company’s overall health and investment viability. This score aggregates various financial metrics and market analysis, suggesting that while there are robust aspects to INSP’s operations, challenges remain, necessitating anchored investor expectations.
Conclusion
With the recent rating downgrade to Equal-Weight and a strong potential upside reflected by Wells Fargo’s price target of $145, Inspire Medical Systems, Inc. presents a complex opportunity for investors. This stock may be particularly appealing to those looking for long-term growth in a sector driven by innovation and demand for healthcare solutions. However, potential investors should remain cognizant of the volatility and risks associated with the stock, particularly given its broader 12-month performance. As the landscape evolves, INSP could be worth monitoring closely, especially if investor sentiment shifts favorably in response to its forthcoming performance reports.